|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0015737,
umls-concept:C0016011,
umls-concept:C0035173,
umls-concept:C0087111,
umls-concept:C0205088,
umls-concept:C0206460,
umls-concept:C0243076,
umls-concept:C0948089,
umls-concept:C1274040,
umls-concept:C1538983,
umls-concept:C2603343
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2003-10-17
|
|
pubmed:abstractText |
In high-risk patients with acute coronary syndromes (ACS), there have been concerns relating to the safety of using low molecular weight heparins (LMWH) in combination with a glycoprotein (GP) IIb/IIIa antagonist, and the continued use of LMWH in patients brought to the cardiac catheterization laboratory for percutaneous coronary intervention (PCI).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Anticoagulants,
http://linkedlifedata.com/resource/pubmed/chemical/Enoxaparin,
http://linkedlifedata.com/resource/pubmed/chemical/Fibrinolytic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Heparin, Low-Molecular-Weight,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Fab Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Glycoprotein GPIIb-IIIa...,
http://linkedlifedata.com/resource/pubmed/chemical/Tyrosine,
http://linkedlifedata.com/resource/pubmed/chemical/abciximab,
http://linkedlifedata.com/resource/pubmed/chemical/eptifibatide,
http://linkedlifedata.com/resource/pubmed/chemical/tirofiban
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1097-6744
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
146
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
628-34
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:14564315-Angina, Unstable,
pubmed-meshheading:14564315-Angioplasty, Balloon, Coronary,
pubmed-meshheading:14564315-Antibodies, Monoclonal,
pubmed-meshheading:14564315-Anticoagulants,
pubmed-meshheading:14564315-Coronary Disease,
pubmed-meshheading:14564315-Drug Therapy, Combination,
pubmed-meshheading:14564315-Enoxaparin,
pubmed-meshheading:14564315-Female,
pubmed-meshheading:14564315-Fibrinolytic Agents,
pubmed-meshheading:14564315-Hemorrhage,
pubmed-meshheading:14564315-Heparin, Low-Molecular-Weight,
pubmed-meshheading:14564315-Humans,
pubmed-meshheading:14564315-Immunoglobulin Fab Fragments,
pubmed-meshheading:14564315-Male,
pubmed-meshheading:14564315-Middle Aged,
pubmed-meshheading:14564315-Myocardial Infarction,
pubmed-meshheading:14564315-Peptides,
pubmed-meshheading:14564315-Platelet Aggregation Inhibitors,
pubmed-meshheading:14564315-Platelet Glycoprotein GPIIb-IIIa Complex,
pubmed-meshheading:14564315-Syndrome,
pubmed-meshheading:14564315-Thrombolytic Therapy,
pubmed-meshheading:14564315-Treatment Outcome,
pubmed-meshheading:14564315-Tyrosine
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
|
|
pubmed:affiliation |
Cardiology Research 1-191, St Luke's Episcopal Hospital, Houston, Tex 77225, USA. jferguson@heart.thi.tmc.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study
|
